spacer
home > ict > summer 2019 > the patient journey
PUBLICATIONS
International Clinical Trials

The Patient Journey





One of the most notable changes in the pharmaceutical industry over the past 10 years is the market shift towards implementing patient-centric practices, programmes, and initiatives as patients are empowered to become more knowledgeable and involved in their treatment. As a result, many life sciences companies are adapting to revolve around the patient at every step of the product lifecycle. This shift from product centricity to patient centricity is moving at varying rates, but it is generally agreed that better patient centricity results in better business and patient outcomes (1).

‘Patient centricity’ can be thought of as the process of designing a product, service, or solution around the patient. In reference to medical products, patient centricity is often the focus during clinical development, with the safety and outcome of every patient in a clinical trial being paramount. During post-approval, the focus is distributed across payers, healthcare providers, regulators, and other company stakeholders. Building patient centricity into every phase of the drug development process requires a comprehensive approach that draws upon numerous stakeholders within the healthcare ecosystem.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Susan Najjar has over 25 years of industry experience with several years in senior leadership and consulting positions. Prior to joining Sciformix, a Covance company, Susan oversaw global marketing activities for Thermo Fisher Scientific’s informatics division, developing growth strategies and implementing innovative marketing programmes. Prior to Thermo, she was accountable for establishing the Gillette Company’s North American Blades and Razors forecasting and planning, executing software product launches at Sun Microsystems, and consulting senior pharma executive teams at Deloitte & Touche. Susan has an MS in Biochemical Engineering from Tufts University, US, and an MBA from MIT Sloan, US.


Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement